QS Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

QS Investors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-166,217	Closed	-$4.39M	–	1717
2019 Q1	$4.39M	Buy	166,217 +483	+0.3%	+$11.4K	0.05%	307
2018 Q4	$3.24M	Hold	165,734	–	–	0.04%	353
2018 Q3	$3.25M	Hold	165,734	–	–	0.03%	439
2018 Q2	$2.75M	Hold	165,734	–	–	0.03%	495
2018 Q1	$2.35M	Sell	165,734 -11,014	-6%	-$163K	0.02%	525
2017 Q4	$2.58M	Hold	176,748	–	–	0.02%	513
2017 Q3	$2.24M	Sell	176,748 -3,527	-2%	-$44.8K	0.02%	577
2017 Q2	$2.14M	Sell	180,275 -6,079	-3%	-$75.6K	0.02%	572
2017 Q1	$2.75M	Buy	186,354 +2,971	+2%	+$48.1K	0.02%	502
2016 Q4	$2.97M	Sell	183,383 -15,379	-8%	-$279K	0.02%	500
2016 Q3	$3.6M	Buy	198,762 +114,316	+135%	+$2.23M	0.03%	485
2016 Q2	$1.39M	Buy	+84,446	New	+$1.37M	0.01%	713
2016 Q1	–	Sell	-12	Closed	-$1K	–	2107
2015 Q4	$1K	Buy	+12	New	+$234	﹤0.01%	1964

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

QS Investors's HZNP Position: Q2 2019 in Review

QS Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 166,217 shares — an estimated $4.39M sold.

QS Investors first reported a position in HZNP in Q4 2015 and held it in 13 quarters. The position peaked at $4.39M in Q1 2019. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

QS Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
QS Investors sold 166,217 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $4.39M.
QS Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 13 quarters.
QS Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.39M in Q1 2019.
272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on QS Investors's 13F filing for Q2 2019, filed 14 Aug 2019.